Diazepam DIAZEPAM CHARTWELL RX, LLC FDA Approved Each tablet for oral administration contains Diazepam, USP 2 mg, 5 mg or 10 mg. Diazepam, USP is a benzodiazepine derivative. Chemically Diazepam, USP is 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin- 2-one. It is an off-white to yellow crystalline powder, insoluble in water. The structural and molecular formulas are as follows: C 16 H 13 ClN 2 O M.W. 284.75 Inactive ingredients for 2 mg, 5 mg or 10 mg includes: lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone and pregelatinized starch. image description
Generic: DIAZEPAM
Mfr: CHARTWELL RX, LLC FDA Rx Only
FunFoxMeds bottle
Substance Diazepam
Route
ORAL
Applications
ANDA070302 ANDA070303 ANDA070304

Drug Facts

Composition & Profile

Strengths
2 mg 5 mg 10 mg
Quantities
90 tablets 90 count
Treats Conditions
Indications Diazepam Is Indicated For The Management Of Anxiety Disorders Or For The Short Term Relief Of The Symptoms Of Anxiety Anxiety Or Tension Associated With The Stress Of Everyday Life Usually Does Not Require Treatment With An Anxiolytic In Acute Alcohol Withdrawal Diazepam May Be Useful In The Symptomatic Relief Of Acute Agitation Tremor Impending Or Acute Delirium Tremens And Hallucinosis Diazepam Is A Useful Adjunct For The Relief Of Skeletal Muscle Spasm Due To Reflex Spasm To Local Pathology Such As Inflammation Of The Muscles Or Joints Or Secondary To Trauma Spasticity Caused By Upper Motor Neuron Disorders Such As Cerebral Palsy And Paraplegia Athetosis And Stiff Man Syndrome Oral Diazepam May Be Used Adjunctively In Convulsive Disorders Although It Has Not Proved Useful As The Sole Therapy The Effectiveness Of Diazepam In Long Term Use That Is More Than 4 Months Has Not Been Assessed By Systematic Clinical Studies The Physician Should Periodically Reassess The Usefulness Of The Drug For The Individual Patient
Pill Appearance
Shape: round Color: white Imprint: CE;202

Identifiers & Packaging

Container Type BOTTLE
UPC
0362135788902 0362135787905 0362135786908
UNII
Q3JTX2Q7TU
Packaging

HOW SUPPLIED Diazepam Tablets, USP for oral administration, are supplied as: 2 mg: White to off white, round scored tablets, debossed with "CE" above bisect "200" on one side and plain on other side. Bottle of 90 Tablets NDC 62135-786-90 5 mg: White to off white, round scored tablets, debossed with "CE" above bisect "201" on one side and plain on other side. Bottle of 90 Tablets NDC 62135-787-90 10 mg: White to off white, round scored tablets, debossed with "CE" above bisect "202" on one side and plain on other side. Bottle of 90 Tablets NDC 62135-788-90. Store DIAZEPAM in a tightly closed container at room temperature between 68°F to 77°F (20°C to 25°C) and out of the light. Dispense in a tight, light- resistant container. Manufactured For: Chartwell RX, LLC. Congers, NY 10920 L71794 Rev. 04/2024 Print Medication Guides at: www.chartwellpharma.com/medguides; PRINCIPAL DISPLAY PANEL Diazepam Tablets, USP CIV 2 mg - NDC 62135-786-90 90s Bottle Label Diazepam Tablets, USP CIV 5 mg - NDC 62135-787-90 90s Bottle label Diazepam Tablets, USP CIV 10 mg - NDC 62135-788-90 90s Bottle label image description image description image description

Package Descriptions
  • HOW SUPPLIED Diazepam Tablets, USP for oral administration, are supplied as: 2 mg: White to off white, round scored tablets, debossed with "CE" above bisect "200" on one side and plain on other side. Bottle of 90 Tablets NDC 62135-786-90 5 mg: White to off white, round scored tablets, debossed with "CE" above bisect "201" on one side and plain on other side. Bottle of 90 Tablets NDC 62135-787-90 10 mg: White to off white, round scored tablets, debossed with "CE" above bisect "202" on one side and plain on other side. Bottle of 90 Tablets NDC 62135-788-90. Store DIAZEPAM in a tightly closed container at room temperature between 68°F to 77°F (20°C to 25°C) and out of the light. Dispense in a tight, light- resistant container. Manufactured For: Chartwell RX, LLC. Congers, NY 10920 L71794 Rev. 04/2024 Print Medication Guides at: www.chartwellpharma.com/medguides
  • PRINCIPAL DISPLAY PANEL Diazepam Tablets, USP CIV 2 mg - NDC 62135-786-90 90s Bottle Label Diazepam Tablets, USP CIV 5 mg - NDC 62135-787-90 90s Bottle label Diazepam Tablets, USP CIV 10 mg - NDC 62135-788-90 90s Bottle label image description image description image description

Overview

Each tablet for oral administration contains Diazepam, USP 2 mg, 5 mg or 10 mg. Diazepam, USP is a benzodiazepine derivative. Chemically Diazepam, USP is 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin- 2-one. It is an off-white to yellow crystalline powder, insoluble in water. The structural and molecular formulas are as follows: C 16 H 13 ClN 2 O M.W. 284.75 Inactive ingredients for 2 mg, 5 mg or 10 mg includes: lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone and pregelatinized starch. image description

Indications & Usage

INDICATIONS Diazepam is indicated for the management of anxiety disorders or for the short- term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

Dosage & Administration

Dosage should be individualized for maximum beneficial effect. While the usual daily dosages given below will meet the needs of most patients, there will be some who may require higher doses. In such cases dosage should be increased cautiously to avoid adverse effects. ADULTS: USUAL DAILY DOSE: Management of Anxiety Disorders and Relief of Symptoms of Anxiety. Depending upon severity of symptoms—2 mg to 10 mg, 2 to 4 times daily Symptomatic Relief in Acute Alcohol Withdrawal. 10 mg, 3 or 4 times during the first 24 hours, reducing to 5 mg, 3 or 4 times daily as needed Adjunctively for Relief of Skeletal Muscle Spasm. 2 mg to 10 mg, 3 or 4 times daily Adjunctively in Convulsive Disorders. 2 mg to 10 mg, 2 to 4 times daily Geriatric Patients, or in the presence of debilitating disease. 2 mg to 2.5 mg, 1 or 2 times daily initially; increase gradually as needed and tolerated PEDIATRIC PATIENTS: Because of varied responses to CNS-acting drugs, initiate therapy with lowest dose and increase as required. Not for use in pediatric patients under 6 months. 1 mg to 2.5 mg, 3 or 4 times daily initially; increase gradually as needed and tolerated Discontinuation or Dosage Reduction of diazepam To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly (see WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence ).

Warnings & Precautions
WARNINGS Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including diazepam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe diazepam concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of diazepam than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking diazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response. Advise both patients and caregivers about the risks of respiratory depression and sedation when diazepam is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see PRECAUTIONS: Drug Interactions ). Abuse, Misuse, and Addiction The use of benzodiazepines, including diazepam , exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death (see DRUG ABUSE AND DEPENDENCE: Abuse ). Before prescribing diazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of diazepam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of diazepam along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate. Dependence and Withdrawal Reactions To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage (a patient-specific plan should be used to taper the dose) (see DOSAGE AND ADMINISTRATION: Discontinuation or Dosage Reduction of diazepam ). Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines, including diazepam, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of diazepam after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) (see DRUG ABUSE AND DEPENDENCE: Dependence ). Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months (see DRUG ABUSE AND DEPENDENCE: Dependence ). Diazepam is not recommended in the treatment of psychotic patients and should not be employed instead of appropriate treatment. Since diazepam has a central nervous system depressant effect, patients should be advised against the simultaneous ingestion of alcohol and other CNS- depressant drugs during diazepam therapy. As with other agents that have anticonvulsant activity, when diazepam is used as an adjunct in treating convulsive disorders, the possibility of an increase in the frequency and/or severity of grand mal seizures may require an increase in the dosage of standard anticonvulsant medication. Abrupt withdrawal of diazepam in such cases may also be associated with a temporary increase in the frequency and/or severity of seizures. Neonatal Sedation and Withdrawal Syndrome Use of diazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate (see PRECAUTIONS: Pregnancy ). Monitor neonates exposed to diazepam during pregnancy or labor for signs of sedation and monitor neonates exposed to diazepam during pregnancy for signs of withdrawal; manage these neonates accordingly.
Boxed Warning
RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including DIAZEPAM, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing DIAZEPAM and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (see WARNINGS ). The continued use of benzodiazepines, including DIAZEPAM, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of DIAZEPAM after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue DIAZEPAM or reduce the dosage (see DOSAGE AND ADMINISTRATION and WARNINGS ).
Contraindications

Diazepam is contraindicated in patients with a known hypersensitivity to diazepam and, because of lack of sufficient clinical experience, in pediatric patients under 6 months of age. Diazepam is also contraindicated in patients with myasthenia gravis, severe respiratory insufficiency, severe hepatic insufficiency, and sleep apnea syndrome. It may be used in patients with open- angle glaucoma who are receiving appropriate therapy, but is contraindicated in acute narrow-angle glaucoma.

Adverse Reactions

Side effects most commonly reported were drowsiness, fatigue, muscle weakness, and ataxia. The following have also been reported: Central Nervous System: confusion, depression, dysarthria, headache, slurred speech, tremor, vertigo Gastrointestinal System: constipation, nausea, gastrointestinal disturbances Special Senses: blurred vision, diplopia, dizziness Cardiovascular System: hypotension Psychiatric and Paradoxical Reactions: stimulation, restlessness, acute hyperexcited states, anxiety, agitation, aggressiveness, irritability, rage, hallucinations, psychoses, delusions, increased muscle spasticity, insomnia, sleep disturbances, and nightmares. Inappropriate behavior and other adverse behavioral effects have been reported when using benzodiazepines. Should these occur, use of the drug should be discontinued. They are more likely to occur in children and in the elderly. Urogenital System: incontinence, changes in libido, urinary retention Skin and Appendages: skin reactions Laboratories: elevated transaminases and alkaline phosphatase Other: changes in salivation, including dry mouth, hypersalivation Antegrade amnesia may occur using therapeutic dosages, the risk increasing at higher dosages. Amnestic effects may be associated with inappropriate behavior. Minor changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after diazepam therapy and are of no known significance. Because of isolated reports of neutropenia and jaundice, periodic blood counts and liver function tests are advisable during long-term therapy. Postmarketing Experience: Injury, Poisoning and Procedural Complications: There have been reports of falls and fractures in benzodiazepine users. The risk is increased in those taking concomitant sedatives (including alcohol), and in the elderly.


Similar Drugs

Related medications based on brand, generic name, substance, active ingredients.

View all similar drugs →